The FDA has sent warning letters to four pharmaceutical companies citing them for omitting and minimizing information about risks and exagerating potential benefits in material promoting their drugs.
The letters order the companies to cease banned marketing behaviors and instruct their employees on rules for promotions, but do not impose any fines or other sanctions.
No comments:
Post a Comment